Table 1 Characteristics of the study cohort.
From: Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients
all patients | |||
|---|---|---|---|
Characteristic | Negative biopsy | Positive biopsy | p value |
Patients, N | 41 | 40 | |
Age*, yr | 0.981 | ||
Mean ± SEM | 61.0 ± 1.3 | 61.5 ± 1.3 | |
Median (IQR) | 62.5 (57.1 - 67.0) | 61.9 (55.6 - 66.6) | |
serum PSA [ng/mL] | 0.026 | ||
Mean ± SEM | 7.5 ± 1.0 | 11.6 ± 1.9 | |
Median (IQR) | 6.2 (4.1 - 8.9) | 7.3 (5.8 - 13.3) | |
SP Dkk-3 [fmol/mg]** | 0.039 | ||
Mean ± SEM | 69.2 ± 9.4 | 100.9 ± 12.3 | |
Median (IQR) | 55.7 (35.8 - 91.2) | 74.5 (41.7 - 124.5) | |
SP PSA [μg/mg]** | 0.317 | ||
Mean ± SEM | 23.8 ± 3.3 | 28.0 ± 3.5 | |
Median (IQR) | 16.8 (8.1 - 35.9) | 19.9 (10.8 - 42.5) | |
Biopsy Gleason score | |||
≤ 6 | 6 | ||
7 | 26 | ||
≥ 8 | 8 | ||
clinical follow-up > 3 yr | |||
Characteristic | Negative biopsy | Positive biopsy | p value |
Patients, N | 25 | 21 | |
Age*, yr | 0.700 | ||
Mean ± SEM | 63.1 ± 1.6 | 61.6 ± 2.3 | |
Median (IQR) | 64.0 (60.9 - 68.9) | 60.5 (53.7 - 69.8) | |
serum PSA [ng/mL] | 0.012 | ||
Mean ± SEM | 8.0 ± 1.6 | 14.3 ± 3.3 | |
Median (IQR) | 6.2 (3.6 - 10.4) | 9.2 (6.5 - 16.0) | |
SP Dkk-3 [fmol/mg]** | 0.027 | ||
Mean ± SEM | 56.3 ± 8.4 | 100.0 ± 16.6 | |
Median (IQR) | 49.6 (22.3 - 76.4) | 76.3 (35.9 - 169.4) | |
SP PSA [μg/mg]** | 0.474 | ||
Mean ± SEM | 23.4 ± 4.5 | 27.4 ± 5.1 | |
Median (IQR) | 16.8 (7.3 - 40.1) | 19.5 (12.7 - 35.0) | |
Biopsy Gleason score | |||
≤ 6 | 3 | ||
7 | 14 | ||
≥ 8 | 4 |